Biotech Graveyard
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle…
Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug
Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. The radiotherapy-activated drug, dubbed JNJ-1900 or NBTXR3, is currently undergoing…
4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy’s phase 3 plans
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in upfront cash to fund the asset’s phase 3 development. In…
Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir
Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area…
Chutes & Ladders—Prominent vaccine critic ousted from HHS
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren…
Eli Lilly sidelines midstage prospect in another pain pipeline pivot
Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain, the company confirmed to Fierce Biotech, in the latest shakeup to a pipeline that has already seen…
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia
Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as…
Inflammation biotech Evommune prices IPO after MapLight’s $250M debut
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. The California biotech announced its IPO…
Sensei drops sole clinical-stage cancer drug, plans layoffs to conserve remaining cash
Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its options. Two weeks ago, the biotech reported phase 1/2 data for its…
Takeda drops AstraZeneca-partnered neurological program after phase 2 failure
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called TAK-341 or…